Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.

Hepato-gastroenterology - 1 Jan 2000

Kasuya Kazuhiko, Tsuchida Akihiko, Nagakawa Yuichi, Suzuki Yoshiaki, Suzuki Minako, Aoki Tatsuya, Abe Yuta, Shimazu Motohide, Itoi Takao, Sofuni Atsushi

Abstract excerpt

BACKGROUND/AIMS: Single nucleotide polymorphism (SNP) of the genes for ATP-binding cassette transporters is related to the side effects of anticancer drugs and that of drug metabolism-related enzyme genes is involved in the activation of gemcitabine (GEM). METHODOLOGY: Forty eight patients treated with adjuvant GEM chemotherapy after pancreatic cancer resection was examined for the SNP of multidrug-resistance 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cytidine Deaminase

Share to Deoxycytidine

Share to Gemcitabine

Share to Pancreatectomy

Share to Ribonucleoside Diphosphate Reductase

Source

Identifiers

PMID: 22155850
DOI: 10.5754/hge11729

Genes

RRM1
GEM
CDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.PMID 22155850Read ↗

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Semantic proximity Read ↗

Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.Semantic proximity Read ↗

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.Semantic proximity Read ↗

Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients.Semantic proximity Read ↗

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.Semantic proximity Read ↗

Clinical pharmacology and pharmacogenetics of gemcitabineSemantic proximity Read ↗

Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluationSemantic proximity Read ↗

CYP1B1 gene polymorphism modifies pancreatic cancer risk but not survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.